Evidence map›Paper›PMID 32420916›Full record

ArticleThe Journal of clinical investigation2020

When viruses collide: hepatitis B virus reactivation after hepatitis C treatment.

Ashwin Balagopal, Chloe L Thio

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ashwin Balagopal
Chloe L Thio

Funding

Immune correlates of acute HBV recovery with and without HIVR01AI116269 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L, THIO, CHLOE L · 2015 to 2019
$3.2M
Characterization of silently HBV-infected hepatocytes in HIV co-infectionR01AI138810 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BALAGOPAL, ASHWIN, THIO, CHLOE L · 2018 to 2021
$3.2M
NIAID NIH HHS R01 AI116269NIAID NIH HHS R01 AI138810
6 · The paper itself

Abstract

Treatment for hepatitis C virus (HCV) with direct-acting antivirals (DAAs) in hepatitis B virus (HBV) coinfection can result in HBV reactivation. In this issue of the JCI, Cheng and colleagues explored the role of interferon signaling in the complex interaction between HBV and HCV using cell lines, mouse models, and samples from people with coinfection. Notably, HCV enhanced interferon signaling, as measured by interferon-stimulated gene (ISG) expression, and decreased HBV transcription and replication. Blockade of interferon signaling reversed the effects on HBV replication. Further, pharmacologic inhibition of HCV replication in vitro and in coinfected humanized mice also reduced interferon signaling and, correspondingly, increased HBV replication. Intriguingly, baseline serum levels of the ISG CXCL10 predicted HBV reactivation in a cohort of coinfected people taking DAAs. Determining how interferon signaling silences HBV transcription and whether serum CXCL10 predicts HBV reactivation in a clinical setting are questions that warrant further investigation.

Indexed as

Antiviral AgentsHepatitis CHepatitis C, ChronicAnimalsHepatitis B virusMiceVirus ActivationAntiviral Agents

Identifiers

PMID32420916
PMCPMC7260028
OpenAlexW3024671994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.